BICYCLERD LIMITED

Comprehensive Financial Health Assessment: BICYCLERD LIMITED

1. Financial Health Score: A- (Stable & Supported)

Explanation: Based on the available corporate data, BICYCLERD LIMITED exhibits a strong structural constitution with no immediate symptoms of distress. The company benefits from the robust "immune system" of being a wholly-owned subsidiary of a publicly traded parent company (Bicycle Therapeutics Plc). The score is an A- rather than a full A+ because, as a subsidiary, its independent financial vital signs (like standalone cash flow and profitability) are not visible in the provided data, meaning its health is intrinsically tied to the circulatory system (funding) of its parent.

2. Key Vital Signs

• Pulse & Respiratory Rate (Compliance & Filing Status): Strong. The company’s statutory pulse is regular and healthy. Accounts are filed up to date (last made up to 31 Dec 2025, next due Sept 2027) with no overdue filings. This indicates a well-functioning administrative nervous system and no signs of regulatory fever.
• Anatomy & Genetics (Corporate Structure): Complex but Secure. The company is a Private Limited Company that underwent a significant "genetic mutation" in 2017, changing its name from BICYCLE THERAPEUTICS LIMITED to BICYCLERD LIMITED. This typically indicates a corporate restructuring—likely aligning with the parent company's public listing or shifting its operational DNA to a specific support function (as indicated by SIC code 82990: Other business support service activities).
• Blood Supply (Capital & Control): Dependent on Parent. The issued share capital stands at a modest £70,580.15. However, the Person with Significant Control (PSC) is Bicycle Therapeutics Plc, which owns more than 75% of the shares, holds over 75% of voting rights, and has the right to appoint/remove directors. This means the company does not need to hunt for its own capital in the wild; it receives regular "blood transfusions" (funding) from its parent as needed.
• Neurological Function (Leadership): High Caliber. The board of directors acts as the brain of the organization. BICYCLERD LIMITED boasts a highly experienced, international board, including high-profile figures from the venture capital and life sciences sectors. This suggests excellent strategic oversight and a low risk of governance dementia.

3. Diagnosis

Diagnosis: Healthy Subsidiary Syndrome (Dependent but Stable)

The financial data reveals a business that is not an independent, self-sustaining organism, but rather a vital organ operating within a larger corporate body. The change of name in 2017 and the current SIC code (business support services) suggest that BICYCLERD LIMITED serves as a specialized support entity—likely handling UK/European operations, R&D, or intellectual property management—for its publicly traded parent, Bicycle Therapeutics Plc.

There are absolutely no symptoms of distress, insolvency, or administrative neglect. The company's filings are punctual, its leadership is deeply experienced, and its ownership structure provides a massive safety net. The only "condition" to note is total reliance on the parent company; if the parent catches a cold, this subsidiary will sneeze.

4. Recommendations

To maintain and improve its financial wellness, BICYCLERD LIMITED should consider the following preventative care measures:

• Monitor Parental Vital Signs: Because the subsidiary relies entirely on the parent for capital and direction, it is critical to keep a close eye on the public financial filings of Bicycle Therapeutics Plc. Any symptoms of cash flow constriction or funding issues at the parent level will directly impact the subsidiary's health.
• Maintain Administrative Hygiene: Continue the excellent compliance track record. Late filings are like infections—they start small but can lead to severe penalties and a compromised corporate reputation. Ensure the newly appointed officers are fully briefed on their statutory duties under UK law.
• Review Intercompany "Transfusion" Agreements: Ensure that any funding provided by the parent (whether through loans, share issuances, or revenue for services) is properly documented and reflects fair market terms. This keeps the corporate veins healthy and protects the directors from potential breaches of fiduciary duty.
• Strategic Health Check: Given the shift to "business support services," the board should regularly evaluate if the company's current operational structure still serves the parent company's long-term strategic goals efficiently.